Navigation Links
Ventus Medical Appoints John McCutcheon as President and CEO

- - Also Announces the expansion of PROVENT(R) Sleep Apnea Therapy in Limited US Markets

BELMONT, Calif., April 9 /PRNewswire/ -- Ventus Medical, Inc. a privately-held, medical device company, focused on transforming the Sleep Disordered Breathing market, today announced the appointment of John McCutcheon as President and Chief Executive Officer, effective April 20, 2009. The company also announced that current CEO Jeffrey Nugent will become Executive Chairman.


Mr. McCutcheon joins Ventus Medical from Emphasys Medical where he was President and CEO for the past seven years. Previously, he was head of Sales and Marketing at Perclose, an Abbott Laboratories company and in senior marketing positions at Devices for Vascular Intervention and Baxter Healthcare.

"John is the ideal leader to drive the commercialization of PROVENT Therapy as a novel treatment of obstructive sleep apnea (OSA). He is a proven leader in the medical device field with nearly 25 years of experience," said Mr. Nugent. "Clinical studies have shown that PROVENT Therapy has the potential to improve the quality of life for millions of people around the world who suffer from this disorder," he added. "We are encouraged by the acceptance we are experiencing at both the physician and patient level at the sleep centers where PROVENT Therapy is currently available."

PROVENT Therapy has been cleared by the Food and Drug Administration and is indicated for the treatment of obstructive sleep apnea. PROVENT Therapy is a daily use, prescription device and works across mild, moderate, and severe OSA.

"I am pleased to join Ventus Medical at this exciting time in the Company's development," said John McCutcheon. "PROVENT Therapy is one of the most innovative products to be introduced into the sleep apnea market in years: it is a convenient, discreet and portable solution. We look forward to working closely with the medical community to meet the need for more patient-friendly, effective sleep apnea treatments."

PROVENT Therapy is currently available in a limited number of markets and is in the process of expanding with the assistance and support of professional sleep physicians in the United States.

Also, Ventus Medical has just been awarded the 2009 Medical Design Excellence Award which recognizes those companies responsible for the ground breaking innovations that are changing the face of healthcare.

Ventus Medical's investors include De Novo Ventures, Mohr Davidow Ventures and the Johnson & Johnson Development Corporation. Information on Ventus Medical and PROVENT Therapy can be found on and

SOURCE Ventus Medical, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. AEterna Zentaris completes management team with the appointment of Chief Medical Officer
2. VisEn Medical Files Action to Invalidate New Caliper Life Sciences Patent
3. China Medical Technologies to Participate in the Morgan Stanleys 2007 China Medical Corporate Day
4. Pathway Medical Technologies Adds Joe Rafferty as VP, Sales, and Moves To Larger Facility to Accommodate Rapid Growth
5. BioMS Medical announces its intention to renew a normal course issuer bid
6. Dr. Amit Dhawan Promoted to Medical Director for The Mattson Jack Group
7. ATS Medical Expands Open Pivot Heart Valve Offerings
8. AGA Medical Corporation Receives FDA and CE Mark Approvals for the AMPLATZER Vascular Plug II
9. Globus Medical Announces Record 2nd Quarter 2007 Results
10. IDM Pharma Names Dr. Jeffrey W. Sherman Chief Medical Officer and Senior Vice President of Research and Development
11. China Medical Technologies Reports First Quarter Financial Results
Post Your Comments:
(Date:10/12/2015)... SAN DIEGO , Oct. 12, 2015 /PRNewswire/ ... for debilitating allergic and inflammatory diseases and conditions, ... Series A preferred stock financing. Concurrent with the ... also entered into a Loan and Security Agreement ... borrow up to $7 million. Patara will use ...
(Date:10/12/2015)... Oct. 12, 2015 VolitionRx Limited (NYSE ... clinical study of its NuQ ® blood-based test for ... issue of Clinical Epigenetics , the official journal of ... collaboration with Lund University, ... MD, PhD, Professor of Surgery and Vice-Dean, Faculty of Medicine. ...
(Date:10/12/2015)... , ... October 12, 2015 , ... LifeTrak , ... launch of LifeTrak Zoom, the world’s first amphibious fitness tracker that seeks to meet ... flexwear technology and accurate heart rate monitoring both in water and on ...
(Date:10/10/2015)... 2015 Am 8. Oktober hat die ... für Kalifornien) ihre Würdigung der International Plasma Awareness ... Aufzeichnungen des Kongresses eintragen lassen. Die IPAW wird ... (PPTA) und ihren Mitgliedsunternehmen unterstützt. Ihre Ziele bestehen ... über Plasmaspenden weltweit , Würdigung des Beitrages ...
Breaking Biology Technology:
(Date:10/8/2015)... , 8. Oktober 2015 ... global tätiges Unternehmen des Bereiches Tracking, hat ... mit der Gefängnisbehörde Virginias (Department of Corrections ... elektronische Überwachungsdienste für alle Strafen geliefert werden, ... Cassell , Präsident für den Amerikanischen Kontinent ...
(Date:10/6/2015)... SAN MATEO, Calif. , Oct. 6, 2015 ... software company, today announced enhancements to its software ... gene expression analysis kit for differential expression in ... Analytic Platform, which is a cloud-based genomic analysis ... to advance scientific discovery from next-generation sequencing efforts. ...
(Date:9/30/2015)... 2015  The U.S. Court of Appeals for the ... in favor of Crossmatch ™, affirming the International ... Suprema and its U.S. partner Mentalix violated Section 337 ... that declares it unlawful to engage in "unfair practices" ... Crossmatch,s patents, the 5,900,993 patent and the 7,203,344 patent. ...
Breaking Biology News(10 mins):